News
HepaFat-AI gains US FDA clearance
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) announces that it has received 510(k) clearance from the US Food and Drug Administration (“FDA”) for HepaFat-AI, a medical device (software)
R&D Update: New Pulmonary Embolism AI Solution Developed
Further to the Company’s announcement on 17 October 2017 (‘Collaborative Partnership commences to develop new AI diagnostic tools’), Resonance Health Ltd is pleased to advise that it has developed a
Execution of Licence Agreement with Telethon Kids Institute and Erasmus University Medical Centre
Resonance Health Ltd is pleased to announce that it has entered into a licence agreement with the Telethon Kids Institute in Perth, Western Australia, and the Erasmus University Medical Centre,
Resonance Health Files New Provisional Patent
Resonance Health Limited is pleased to announce that it has filed a provisional patent covering the application of novel Antisense Oligonucleotides (ASOs) to treat liver related disease.
Resonance Health News – April 2020
Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities. To read the newsletter please click here
Resonance Health Partners with Siemens Healthineers
Resonance Health is pleased to announce that it has entered into a Solution Partner Agreement with Siemens Healthcare GmbH (Siemens Healthineers), a leading medical technology company headquartered in Erlangen, Germany,